Otsuka’s Voyxact stabilised kidney function at two years in Phase III IgAN trial

Phase 3positiveVoyxactPositive

AI Analysis

Summary

Otsuka announced that its Phase III VISIONARY trial showed Voyxact stabilised kidney function at two years in IgAN patients, supporting the company's rolling sBLA submission for the drug.

Clinical Trial Data

Phase

Phase III

Primary Endpoint

Met

Outcome Details

Stabilised kidney function at two years in Phase III IgAN trial

Importance:7/10

Sentiment:

0.75

Phase 3 trialPositive datasBLA submissionKidney diseaseIgAN

Related Companies

$OTSKF

Read the original article

Published by Clinical Trials Arena on August 4, 2026 2:19 PM

Read Original